Aspirin reduces the risk of type 2 diabetes associated with COVID-19

Aspirin reduces the risk of type 2 diabetes associated with COVID-19

Abstract This study aimed to determine whether daily low-dose aspirin reduces the risk of type 2 diabetes (T2D) associated with COVID-19. A longitudinal cohort of 200,000 adults followed from 2018 to 2022 was analyzed, comparing T2D incidence between aspirin users and non-users. Propensity score mat...

Full description

Saved in:
Bibliographic Details
Main Authors: Valentina Trimarco, Raffaele Izzo, Daniela Pacella, Maria Virginia Manzi, Stanislovas S. Jankauskas, Paola Gallo, Francesco Rozza, Giuseppe Giugliano, Alessandra Spinelli, Giovanni Esposito, Roberto Piccinocchi, Gaetano Piccinocchi, Carmine Morisco, Maria Lembo, Gaetano Santulli, Bruno Trimarco
Format: Article
Language:English
Published: Nature Portfolio 2025-06-01
Series:npj Metabolic Health and Disease
Online Access:https://doi.org/10.1038/s44324-025-00072-3
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract This study aimed to determine whether daily low-dose aspirin reduces the risk of type 2 diabetes (T2D) associated with COVID-19. A longitudinal cohort of 200,000 adults followed from 2018 to 2022 was analyzed, comparing T2D incidence between aspirin users and non-users. Propensity score matching was used to balance the groups. The incidence of T2D was substantially lower in the aspirin group, with Cox regression showing a 52% risk reduction. Kaplan-Meier analysis confirmed a significant divergence in cumulative T2D risk after two years. This protective effect was observed both before and during the COVID-19 pandemic, with a stronger association during the pandemic period. These findings indicate that daily low-dose aspirin significantly reduces the risk of COVID-19-associated new-onset T2D, highlighting the role of inflammation in the pathogenesis of T2D triggered or unmasked by COVID-19.
ISSN:2948-2828

Similar Items